THERANOSTICS 2016* Richard Baum
Zentralklinik Bad Berka, THURINGIA, Germany
- This delegate is presenting an abstract at this event.
Presentations this author is a contributor to:
Phase I/II open-label trial to evaluate the safety and preliminary efficacy of 177Lu-OPS201, a radiolabeled somatostatin receptor antagonist, in patients with somatostatin receptor-positive, progressive gastroenteropancreatic neuroendocrine tumors (#57)
8:30 AM
Rod Hicks
Conference Breakfast: Moderated Poster Walk - Neuroendocrine tumours
Two Decades of THERANOSTICS in Neuroendocrine Tumors – Past, Presence and Future of Peptide Receptor Radionuclide Therapy (PRRT) (#8)
1:00 PM
Richard Baum
Optimising Peptide Receptor Radionuclide Therapy (PRRT)